文献速递胸部肿瘤

通过筛查、肺结节或两者均无项目诊断的肺癌:密西西比三角洲队列中早期肺癌检测(DELUGE)的前瞻性观察研究

Lung Cancer Diagnosed Through Screening, Lung Nodule, and Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort.
PubMed 文献 · J Clin Oncol · 2022-03-08

该前瞻性观察研究纳入2015年至2021年5月登记的22886例患者,比较低剂量计算机断层扫描筛查(LDCT)、肺结节项目和 multidisciplinary care 项目诊断肺癌的临床分期、手术切除率及生存率。结果显示LDCT和肺结节项目诊断的肺癌I-II期比例和治愈性手术率高于 multidisciplinary care 项目,3年和5年总生存率也更高。USPSTF 2021标准下仅54%肺癌患者符合LDCT资格。

要点

  • LDCT和肺结节项目诊断的肺癌I-II期比例分别为61%和60%,高于 multidisciplinary care 项目的44%。
  • LDCT、肺结节和 multidisciplinary care 项目的3年总生存率分别为80%、64%和49%。
  • 仅54%肺癌患者符合USPSTF 2021 LDCT筛查资格。

核心结论

  • LDCT和肺结节项目具有互补性,可扩大不同风险人群获得早期肺癌检测和治愈性治疗的机会。
  • 实施肺结节项目可能减轻早期肺癌检测可及性方面新出现的差异。

研究设计与样本

  • 前瞻性观察研究,纳入2015年至2021年5月在密西西比三角洲队列早期检测项目中登记的患者,并与 multidisciplinary care 项目中管理的患者进行比较。
  • 共纳入22886例患者:LDCT组5659例,肺结节组15461例, multidisciplinary care 组1766例。

主要发现

  • LDCT、肺结节和 multidisciplinary care 项目分别诊断肺癌150例、698例和1010例。
  • 临床I或II期诊断比例分别为61%、60%和44%,IV期比例分别为19%、20%和29%(P = .0005)。
  • 接受治愈性意图手术的比例分别为47%、42%和32%(P < .0001)。
  • 3年总生存率分别为80%(95% CI,73至88)、64%(60至68)和49%(46至53)。
  • 5年总生存率分别为76%(67至87)、60%(56至65)和44%(40至48)。

关键数值与推荐

  • 在1858例肺癌患者中,仅46%符合USPSTF 2013标准LDCT筛查资格,54%符合2021标准资格。
  • 即使所有符合USPSTF 2021标准的患者均纳入LDCT,肺结节项目仍可检测整个队列中20%的I-II期肺癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lung cancer screening saves lives, but implementation is challenging. We evaluated two approaches to early lung cancer detection-low-dose computed tomography screening (LDCT) and program-based management of incidentally detected lung nodules. METHODS: A prospective observational study enrolled patients in the early detection programs. For context, we compared them with patients managed in a Multidisciplinary Care Program. We compared clinical stage distribution, surgical resection rates, 3- and 5-year survival rates, and eligibility for LDCT screening of patients diagnosed with lung cancer. RESULTS: From 2015 to May 2021, 22,886 patients were enrolled: 5,659 in LDCT, 15,461 in Lung Nodule, and 1,766 in Multidisciplinary Care. Of 150, 698, and 1,010 patients diagnosed with lung cancer in the respective programs, 61%, 60%, and 44% were diagnosed at clinical stage I or II, whereas 19%, 20%, and 29% were stage IV (P = .0005); 47%, 42%, and 32% had curative-intent surgery (P < .0001); aggregate 3-year overall survival rates were 80% (95% CI, 73 to 88) versus 64% (60 to 68) versus 49% (46 to 53); 5-year overall survival rates were 76% (67 to 87) versus 60% (56 to 65) versus 44% (40 to 48), respectively. Only 46% of 1,858 patients with lung cancer would have been deemed eligible for LDCT by US Preventive Services Task Force (USPSTF) 2013 criteria, and 54% by 2021 criteria. Even if all eligible patients by USPSTF 2021 criteria had been enrolled into LDCT, the Nodule Program would have detected 20% of the stage I-II lung cancer in the entire cohort. CONCLUSION: LDCT and Lung Nodule Programs are complementary, expanding access to early lung cancer detection and curative treatment to different-risk populations. Implementing Lung Nodule Programs may alleviate emerging disparities in access to early lung cancer detection.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Osarogiagbon RU, Liao W, Faris NR, et al. Lung Cancer Diagnosed Through Screening, Lung Nodule, and Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort. J Clin Oncol. 2022. PMID: 35258994. doi:10.1200/JCO.21.02496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。